克里唑替尼一线医治肺癌的确好于放化疗

南亚先生 2021年12月26日09:51:02克唑替尼克里唑替尼一线医治肺癌的确好于放化疗已关闭评论阅读模式
顾问微信:yaodaoyaofang

印度全球直邮药房:经济寻药,源头正品;助力生命,精准抗癌! —— 顾问微信:yaodaoyaofang

克里唑替尼一线医治肺癌的确好于放化疗 。
摘 要:吉非替尼胶襄。【微信号码:yaodaoyaofang】:南南和晨晨来源于:桓兴医讯英国《临床肿瘤学杂志》2022年5月16日线上先给--对一项克里唑替尼一线医治与一线有机化学治疗法相比较研究的总生活的最后剖析:来源于PROFILE 1014实验的結果BenjaminJ. Solomon, Dong-Wan Kim, Yi-Long Wu,Kazuhiko Nakagawa, Tarek Mekhail,EnriquetaFelip...Show More目地PROFILE 1014是一项III期临床试验,在晚后期内转性淋巴肿瘤蛋白激酶(ALK)呈阳性的非鳞非小细胞肺癌病患者中对克里唑替尼一线医治与一线有机化学治疗法开展了较为。在这里,大家对总存活(OS)的最后結果给予汇报。病患者与办法对病患者随机分组,一组内服克里唑替尼250mg,每日2次(n=172),另一组静脉血管给与培美曲塞500mg/m2 顺铂75mg/m2或卡铂(浓度值时间曲线下总面积5-6mg·mL/min),每3周一个疗程,数最多6个治疗过程(n=171)。恶性肿瘤进度后容许交叉式到克里唑替尼组。选用一种分层次多数秩检测和一种预设保秩构造无效時间实体模型表述交叉式效用,对总存活开展剖析。結果对2组总生活的负相关随诊時间大概为46个月,有机化学治疗法组,144名(84.2%)病患者在之后的诊治中接纳了克里唑替尼。总生活的风险之比0.760(95%CI,0.548-1.053;双尾P=0.0978)。克里唑替尼组并未到负相关总存活時间(NR),有机化学治疗法组负相关总存活時间为47.5个月(95%CI,32.2个月至NR)。克里唑替尼组4年存活几率为56.6%(95%CI,48.3%-64.1%),有机化学治疗法组49.1%(95%CI,40.5%-57.1%)。对交叉式效用校准后,说明克里唑替尼组总存活有改进(风险比,0.346;95%自举CI,0.081-0.718)。在克里唑替尼医治且接着进行了ALK酪氨酸激酶受体的病患者中,观查到最多的总存活時间。沒有发觉新的安全性特点(过虑词)。结果PROFILE 1014科学研究的最后剖析为ALK重新排列的非小细胞肺癌病患者的总存活带来了新的标准,突显了克里唑替尼对提升这类病患者存活时长的益处。Final Overall Survival Analysis Froma Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE1014Benjamin J.Solomon, Dong-Wan Kim,Yi-Long Wu, KazuhikoNakagawa, Tarek Mekhail,Enriqueta Felip...Show MorePurposeThe phase III PROFILE 1014 trial compared crizotinib withchemotherapy as first-line treatment in patients with anaplastic lymphomakinase (ALK) –positive advanced nonsquamous non–small-cell lung cancer. Here,we report the final overall survival (OS) results.Patients and MethodsPatients were randomly assigned to receive oralcrizotinib 250 mg twice daily (n = 172) or intravenous pemetrexed 500 mg/m2 plus cisplatin 75mg/m2 or carboplatin(area under the concentration–time curve of 5 to 6 mg·mL/min) every 3 weeks fora maximum of six cycles (n = 171). Crossover to crizotinib was permitted afterdisease progression. OS was analyzed using a stratified log-rank test and aprespecified rank-preserving structural failure time model to account forcrossover.ResultsMedian follow-up duration for OS was approximately 46months for both arms. In the chemotherapy arm, 144 patients (84.2%) receivedcrizotinib in subsequent lines. Hazard ratio for OS was 0.760 (95% CI, 0.548 to1.053; two-sided P = .0978). Median OS was not reached (NR) withcrizotinib (95% CI, 45.8 months to NR) and 47.5 months with chemotherapy (95%CI, 32.2 months to NR). Survival probability at 4 years was 56.6% (95% CI,48.3% to 64.1%) with crizotinib and 49.1% (95% CI, 40.5% to 57.1%) with chemotherapy.After crossover adjustment, there was an improvement in OS that favoredcrizotinib (hazard ratio, 0.346; 95% bootstrap CI, 0.081 to 0.718). The longestOS was observed in crizotinib-treated patients who received a subsequent ALKtyrosine kinase inhibitor. No new safety signals were identified.ConclusionThe final analysis of the PROFILE 1014 study provides anew benchmark for OS in patients with ALK-rearranged non–small-cell lungcancer and highlights the benefit of crizotinib for prolonging survival in thispatient population.药道网给予近期的药物新闻资讯,聚集 印度的全世界海淘药店:吃克唑替尼便秘吃什么药。

药道全球直邮药房客服微信:yaodaoyaofang (敬请保留,以备急用!)
weinxin
客服微信
全程为您提供顾问式服务!
  • 本站大部分涉及到的医学信息均收集于网络,只做学习和交流使用,版权归原作者所有。这些资料不应该被视为医生的建议或代替。若您需要在医学上作出正确的决策,请咨询您的治疗医生了解更多细节。
  • 克里唑替尼一线医治肺癌的确好于放化疗
克唑替尼(Xalkori) 克唑替尼

克唑替尼(Xalkori)

克唑替尼是一种靶向抗癌药物。它是一种治疗晚期非小细胞肺癌(NSCLC)的药物。 它适用于间变性淋巴瘤激酶 (ALK) 或 ROS1 基因发生变化的 NSCLC。您的医生会检查您的癌症是否存在这些基因变...